Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance

Journal of Clinical Microbiology

Volumn 41, Issue 7, 2003, Pages 2900-2907

  Galli, R A ^a   Sattha, B ^a   Wynhoven, B ^a   O'Shaughnessy, M V ^a   Harrigan, P R ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; WILD TYPE;

AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; MUTATION; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0038168521     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.7.2900-2907.2003     Document Type: Article

References (23)

1. Baxter, J. D., D. L. Mayers, D. N. Wentworth, J. D. Neaton, M. L Hoover, M. A. Winters, S. B. Mannheimer, M. A. Thompson, D. I. Abrams, B. J. Brizz, J. P. Ioannidis, T. C. Merigan, et al. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14:F83-F93.
2. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. 2001. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2:276-313.
3. Call, S.A., M. S. Saag, A. O. Westfall, J. L. Raper, S. V. Pham, J. M. Tolson, N. S. Hellman, G. A. Cloud, and V. A. Johnson. 2001. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J. Infect. Dis. 183:401-408.
4. D'Aquila, Richard T. 2000. Limits of resistance testing. Antivir. Ther. 5:71-76.
5. Deeks, S. G., N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen:antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 179:1375-1381.
6. Demeter, L. M., R. D'Aquila, O. Weislow, E. Lorenzo, A. Erice, J. Fitzgibbon, R. Shafer, D. Richman, T. M. Howard, Y. Zhao, E. Fisher, D. Huang, D. Mayers, S. Sylvester, M. Arens, K. Sannerud, S. Rasheed, V. Johnson, D. Kuritzkes, P. Reichelderfer, A. Japour, et al. 1998. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. J. Virol. Methods 75:93-104.
7. Dunne, A. L., F, M. Mitchell, S. K. Coberly, N. S. Hellmann, J. Hoy, A. Mijch, C. J. Petropoulos, J, Mills, and S. M. Crowe. 2001. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15:1471-1475.
8. Durant, J., P. Clevenbergh, P. Halfon, P. Delguidice, S. Porsin, P. Simonet, N. Montagne, C. A. Boucher, J. M. Schapiro, and P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy:the VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
9. Erali, M., S. Page, L. G. Reimer, and D. R. Hillyard. 2001. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J. Clin. Microbiol. 39:2157-2165.
10. Galli, R., B. Wynhoven, and R. Harrigan. 2002. Quality management of sequence-based methods for measuring HIV-1 drug resistance. Am. Clin. Lab. 21:13-15.
11. Hammond, J., C. Calef, B. Larder, R. F. Schinazi, and J. Mellors. 1998. Mutations in retroviral genes associated with drug resistance. In B. T. Korber, C. Kuiken, B. Foley, B. Hahn, F. McCutchan, J. Mellors, and J. Sodrowski (ed.), Human retroviruses and AIDS: a compilation and analysis of nucleic and amino acid sequences. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N. Mex.
12. Harrigan, P. R., K. Hertogs, W. Verbiest, R. Pauwels, B. Larder, S. Kemp, S. Bloor, B. Yip, R. Hogg, C, Alexander, and J. S. Montaner. 1999. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 13:1863-1871.
13. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S, M. Hammer, V. Johnson, D. Kuritzkes, C, Loveday, J, W. Mellors, B. Clotet, B, Conway, L. M. Demeter, S. Vella, D. M, Jacobsen, and D, D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283:2417-2426.
14. Richman, D, D. 2000. Principles of HIV resistance testing and overview of assay performance characteristics. Antivir. Ther. 5:27-31.
15. Romano, L., G, Venturi, S, Bloor, R. Harrigan, B. A, Larder, J. C. Major, and M, Zazzi. 2002. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J. Infect. Dis. 185:898-904.
16. Schuurman, R., D, Brambilla, T. de Groot, D, Huang, S, Land, J. Bremer, I. Benders, and C, A. Boucher, 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retrovir. 18:243-248.
17. Schuurman, R., L. Demeter, P. Reichelderfer, J. Tijnagel, T. de Groot, and C. Boucher. 1999. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 37:2291-2296.
18. Servais, Jean, Jean-Marc Plesseria, Christine Lambert, Elodie Fontaine, Isabelle Robert, Vic Arendt, Therese Staub, Francois Schneider, Robert Hemmer, and Jean-Claude Schmit. 2002. Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations. Antivir. Ther. 6:239-248.
19. Shafer, R. W., A. Warford, M. A. Winters, and M. J. Gonzales. 2000. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J. Virol. Methods 86.143-153.
20. Shafer, R. W., K. Hertogs, A. R. Zolopa, A. Warford, S. Bloor, B. J. Betts, T. C. Merigan, R. Harrigan, and B. A. Larder. 2001. High degree of inter-laboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J. Clin. Microbiol. 39:1522-1529.
21. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The ClustaIX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic-Acids Res. 24:4876-4882.
22. Tural, C., L. Ruiz, C. Holtzer, J. Schapiro, P. Viciana, J. Gonzalez, P. Domingo, C. Boucher, C. Rey-Joly, and B. Clotet. 2002. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16:209-218.
23. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.